Search terms
Results 31 - 40 of 90 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 9

Conversely, lifestyle, diabetes, dyslipidemia, cigarette smoking and hypertension contribute to most of the population-attributable risk in the large, international INTERHEART study of acute ...

Date : 01/09/2008

The study ? a systematic review and meta-analysis ? published online today (Tuesday) in the European Heart Journal [1], found that in the two hours immediately after an angry outburst, a perso ? risk ...

Date : 04/03/2014

People taking anti-psychotic drugs and anti-depressant drugs have a much higher risk of dying during an acute coronary event of a fatal arrhythmia than the rest of the population, finds a Finnish ...

Date : 15/11/2011

In the Western Norway B-vitamin intervention trial, a total of 3,090 patients with angiographically verified (established) heart disease, mainly stable angina pectoris and 2 or 3 vessel coronary ...

Date : 04/09/2007

Number of children is emerging as a novel factor that influences the risk for some cardiovascular diseases (CVD), and in some societies in both parents, according to Professor Vera Regitz-Zagrosek, ...

Date : 03/02/2017

HDL: a question of quantity or quality? [...]recently it was undisputed dogma that high-density lipoprotein cholesterol (HDL-C) has solely atheroprotective properties. Recently, however, this view ...

Date : 29/08/2016

First baseline data by REACH supports and extends ESC?s Euroaspire findings REACH extends the Euroaspire findings in post MI European patients to include other groups of patients (patients in ...

Date : 17/01/2006

Pneumonia or sepsis in adults that results in hospital admission is associated with a six-fold increased risk of cardiovascular disease in the first year, according to research published today in the ...

Date : 02/08/2017

The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) already published and presented during AHA 20181 randomized 8179 patients with established ...

Date : 06/05/2019

Sunday 31 August: Long term results for the investigational monoclonal antibody alirocumab, show that in addition to significantly reducing cholesterol on top of regular statin therapy, it also ...

Date : 31/08/2014